Evidence map›Paper›PMID 42156415›Full record

ArticleScientific reports2026

MultiTask learning AI system to assist BCC diagnosis with dual explanation.

Iván Matas, Carmen Serrano, Francisca Silva-Clavería, Amalia Serrano, Tomás Toledo-Pastrana, Begoña Acha

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Iván MatasDepartamento Teoría de la Señal y Comunicaciones, Escuela Técnica Superior de Ingeniería, Universidad de Sevilla, Seville, Andalucía, Spain. imatas@us.es.
Carmen SerranoDepartamento Teoría de la Señal y Comunicaciones, Escuela Técnica Superior de Ingeniería, Universidad de Sevilla, Seville, Andalucía, Spain.
Francisca Silva-ClaveríaServicio de Dermatología, Hospital Universitario Virgen Macarena, Seville, Andalucía, Spain.
Amalia SerranoServicio de Dermatología, Hospital Universitario Virgen Macarena, Seville, Andalucía, Spain.
Tomás Toledo-PastranaHospitales Quirón Salud Infanta Luisa y Sagrado Corazón, Quirón Salud, Seville, Andalucía, Spain.
Begoña AchaDepartamento Teoría de la Señal y Comunicaciones, Escuela Técnica Superior de Ingeniería, Universidad de Sevilla, Seville, Andalucía, Spain.

Funding

Agencia de Innovación y Desarrollo de Andalucía PROYEXCEL_00889Ministerio de Ciencia e Innovación PID2021-127871OB-I00
6 · The paper itself

Abstract

Basal cell carcinoma (BCC) accounts for 75% of all skin cancers. Currently, all major public hospitals in Spain have a dermatology care protocol that includes teledermatology. This has created an overload for hospital dermatologists, which could be alleviated with an AI tool for prioritization. Several AI systems have been proposed for this purpose, but the lack of transparent diagnostic explanations limits their clinical acceptance and implementation. This fact motivates the present study, which aims to develop an AI tool focused on detecting BCC from dermoscopic images incorporating dermatologist diagnostic criteria to enhance reliability. Specifically, the BCC diagnostic criterium is that a lesion is not considered BCC if it exhibits pigment network pattern, and that a lesion is considered BCC if it exhibits at least one of these BCC patterns: ulceration, ovoid nest, multi globules, maple-leaf, spoke wheel, arborizing telangiectasia. We analyzed 1,559 dermoscopic images collected from 60 primary care centers in Andalusia. Four dermatologists annotated the images as exhibiting or not each of the seven possible BCC patterns. As there is no established Ground Truth to determine the BCC patterns present in a lesion, we propose an Expectation-Maximization consensus algorithm to consolidate the multi-rater annotations into a unified standard reference (SR). As an additional novelty, the system incorporates the symbolic reasoning of dermatologists, who base their diagnoses on BCC patterns shown in lesions. To this end, a multitask learning (MTL) system based on MobileNet-V2 was designed. This system can rapidly triage BCC and non-BCC lesions while providing clinical information justifying this classification. This system also provides GradCAM-based maps to dermatologists to improve its reliability and confidence. Three evaluations were performed on the AI system. First, a performance analysis was conducted to evaluate the AI tool’s ability to classify lesions as BCC or non-BCC. In this analysis, the model achieved 90% accuracy (precision=0.90, recall=0.89). The second evaluation analyzed whether the detected patterns agreed with dermoscopic criteria. Notably, at least one clinically relevant BCC pattern was correctly identified in 99% of BCC-positive cases, and the pigment-network negative criterion was met in 95% of non-BCC cases. A comparison of the GradCAM maps with the dermatologist’s manual delineation demonstrated strong colocalization with dermatologist-segmented regions (mean foreground density 0.57 vs. background 0.16), confirming alignment of the visual focus of experts. This work introduces the first clinically validated dual-explanation AI system that combines high-accuracy BCC detection with transparent, pattern-based explanations. This approach closes the critical gap between AI performance and clinical trust in teledermatology, positioning the system for immediate deployment in primary care. Future work will focus on determining the extent to which this dual explanation system improves dermatologists’ confidence.

Indexed as

Basal cell carcinomaComputer-aided diagnosisDeep learningDermoscopyTelemedicineXAI

Identifiers

PMID42156415
PMCPMC13187323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.